TRDA (Entrada Therapeutics, Inc.) PDUFA Date | FDA Catalyst & Approval Status

Jun 2, 2026

Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study

Entrada Therapeutics announced that the independent Data Monitoring Committee has recommended the initiation of Cohort 2 at an increased dose of 10 mg/kg in the ELEVATE-45-201 study. This decision follows the review of safety and pharmacokinetic data from Cohort 1. The study aims to evaluate the treatment of Duchenne muscular dystrophy with ENTR-601-45, and data from Cohort 1 is expected to be reported in mid-2026.

Jun 2, 2026

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 1, 2026

Entrada Therapeutics has granted 18,600 restricted stock units to three new non-executive employees as part of its 2025 Inducement Equity Plan. This move, approved by the Compensation Committee, aims to incentivize new hires in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over time, contingent on the employees' continued service.

May 19, 2026

Meet Andrew and JJ, living with Duchenne muscular dystrophy Corporate Presentation May 2026 Disclaimer May 2026 2 This presentation has been prepared by Entrada Therapeutics, Inc. (“Entrada”) and shall not

Entrada Therapeutics, Inc. has presented data from a study on ENTR-601-50, a potential treatment for Duchenne muscular dystrophy (DMD), highlighting significant exon skipping and dystrophin restoration in preclinical models. The findings revealed noteworthy improvements in muscle function observed as early as two weeks following a single dose. Entrada is also optimistic that its next-generation exon skippers can effectively target muscle regeneration, providing therapeutic benefits while being safe and flexible for dosing.

May 11, 2026

Entrada Therapeutics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Johnson Fistel, PLLP is investigating potential claims for investors of Entrada Therapeutics, Inc. regarding possible recovery of losses under federal securities laws. This follows Entrada's announcement of topline results from its ELEVATE-44-201 study, where the stock price dropped significantly. Although some results were described as positive, issues such as lower-than-expected plasma exposure have raised concerns about transparency. The firm is urging affected investors to reach out for assistance in recovering their losses.

May 7, 2026

▼ -57.3%on this newsshared move

Entrada Therapeutics Reports First Quarter 2026 Financial Results

Entrada Therapeutics reported strong financial results for Q1 2026, highlighting positive topline data from the ELEVATE-44-201 study in Duchenne muscular dystrophy. The company has a robust cash position of $255 million, expected to last into Q3 2027. Upcoming data from additional clinical studies is anticipated, marking significant milestones in their neuromuscular pipeline.

May 7, 2026

▼ -57.3%on this newsshared move

Entrada Therapeutics Announces Positive Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study

Entrada Therapeutics announced positive topline results from Cohort 1 of its Phase 1/2 ELEVATE-44-201 study, showing favorable safety and tolerability for ENTR-601-44 in participants with Duchenne muscular dystrophy. The study achieved significant improvements in dystrophin levels and Time to Rise velocity compared to placebo. All participants have progressed to the open-label Phase 2 portion, with expectations for further data by year-end 2026.

May 6, 2026

Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study on May 7, 2026

Entrada Therapeutics is set to announce topline results from the first cohort of participants treated with ENTR-601-44 in their Phase 1/2 ELEVATE-44-201 study on May 7, 2026. This double-blind, placebo-controlled study aims to provide insights into the efficacy of their treatment for Duchenne muscular dystrophy. An investor webcast and conference call will follow to discuss the results in detail.

Mar 3, 2026

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 2, 2026

Entrada Therapeutics has announced the grant of 12,990 restricted stock units (RSUs) to two new non-executive employees as part of its 2025 Inducement Equity Plan. This move, approved by the Compensation Committee, aims to incentivize the new hires under Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over a structured timeline, aligning employee retention with company growth.

Feb 26, 2026

▲ +6.8%on this newsshared move

Entrada Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

Entrada Therapeutics reported its financial results for Q4 and full year 2025, highlighting a positive recommendation from the Data Monitoring Committee to initiate a second cohort in the ELEVATE-44-201 study. The company expects to report data from multiple clinical cohorts in 2026 and has a cash runway into Q3 2027. However, it also reported a significant net loss and a decrease in collaboration revenue compared to the previous year.

Feb 17, 2026

Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study

Entrada Therapeutics announced that the independent Data Monitoring Committee has recommended the initiation of Cohort 2 at an increased dose of 12 mg/kg in the ELEVATE-44-201 study. Patients from Cohort 1 have progressed to the open label Phase 2 portion, with data from Cohort 1 expected in Q2 2026 and Cohort 2 data by year-end. The study aims to evaluate the treatment of Duchenne muscular dystrophy.

Feb 4, 2026

▼ -8.2%on this news

Entrada Therapeutics to Present at Upcoming Investor Conferences

Entrada Therapeutics, Inc. (Nasdaq: TRDA) announced its participation in two upcoming investor conferences. CEO Dipal Doshi will engage in fireside chats at the Guggenheim Emerging Outlook: Biotech Summit on February 11, 2026, and the TD Cowen 46th Annual Health Care Conference on March 3, 2026. Live webcasts will be available on the company's website.

Jan 8, 2026

TRDAClinical Trials

Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases

Entrada Therapeutics has announced significant progress in its RNA-based programs targeting neuromuscular and ocular diseases. The company is set to report data from its ELEVATE clinical studies for Duchenne muscular dystrophy in 2026 and is expanding its portfolio with a new candidate for Usher syndrome. Additionally, Entrada aims to initiate a Phase 1/2 clinical study for ENTR-601-50 and plans to submit regulatory applications for ENTR-601-51 by the end of 2026. With a strong financial position extending through 2027, Entrada is positioned for continued advancement in its therapeutic development.

Dec 17, 2025

Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Entrada Therapeutics, Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. CEO Dipal Doshi will deliver the presentation, which will be available via live webcast and archived for 30 days. The company focuses on developing therapies targeting intracellular mechanisms for various diseases, including neuromuscular and ocular conditions.

Dec 4, 2025

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Entrada Therapeutics has granted inducement equity awards to five new non-executive employees as part of its 2025 Inducement Equity Plan. The grants include 40,650 restricted stock units and options for 38,850 shares, with a vesting schedule tied to continued employment. This move aligns with Nasdaq Listing Rule 5635(c)(4) and aims to enhance the company's workforce.

Nov 6, 2025

Entrada Therapeutics Reports Third Quarter 2025 Financial Results

Entrada Therapeutics reported its third quarter 2025 financial results, highlighting progress in its Duchenne muscular dystrophy (DMD) programs. The company is set to deliver data from the ELEVATE-44-201 and ELEVATE-45-201 studies in 2026. Despite a significant net loss and decreased collaboration revenue, Entrada maintains a strong cash position to support its operations into 2027.

Sep 5, 2025

Entrada Therapeutics Announces Recipients of Third Annual DREAMS Grant Program

Entrada Therapeutics has announced the recipients of its third annual DREAMS Grant Program, awarding $50,000 each to Jett Foundation and Parent Project aps. These grants aim to enhance equity and accessibility for individuals living with Duchenne muscular dystrophy. The announcement coincides with World Duchenne Awareness Day, highlighting the company's commitment to the Duchenne community.

Aug 6, 2025

Entrada Therapeutics Reports Second Quarter 2025 Financial Results

Entrada Therapeutics reported its second quarter 2025 financial results, highlighting significant advancements in clinical trials for its Duchenne muscular dystrophy therapies. Notably, the first patient was dosed in the ELEVATE-44-201 study, with data anticipated in H1 2026. The company's strong cash position of $354 million is expected to support its operations until Q2 2027, although it reported a net loss of $43.1 million in the latest quarter due to increased R&D expenses. Entrada is also expanding its leadership team to facilitate its growing pipeline.

Jun 3, 2025

Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

Entrada Therapeutics has appointed Dr. Maha Radhakrishnan to its Board of Directors. Dr. Radhakrishnan brings extensive experience in global drug development, which will support Entrada's efforts in advancing its Duchenne muscular dystrophy programs. The company is focused on launching multiple clinical trials this year to address urgent treatment needs.

May 28, 2025

Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

Entrada Therapeutics has received authorization from EU health authorities to initiate the ELEVATE-45-201 clinical study, focusing on ENTR-601-45 for patients with Duchenne muscular dystrophy amenable to exon 45 skipping. The Phase 1/2 study aims to evaluate the safety and efficacy of the treatment. The company plans to start the trial in Q3 2025, building on recent authorizations for other studies.

Entrada Therapeutics Reports First Quarter 2025 Financial Results

Entrada Therapeutics announced its financial results for the first quarter of 2025, highlighting regulatory approval for the ELEVATE-44-201 clinical study in the EU. The company is set to commence this study, along with others focused on Duchenne muscular dystrophy, in 2025. Despite a reported net loss of $17.3 million, Entrada maintains a solid cash position expected to last until at least Q2 2027, positioning itself strongly for upcoming clinical developments.

Mar 24, 2025

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

Entrada Therapeutics has announced that it received authorization from the UK's Medicines and Healthcare Products Regulatory Agency to initiate the ELEVATE-45-201 clinical study. This Phase 1/2 trial will evaluate the safety and efficacy of ENTR-601-45, designed for patients with Duchenne muscular dystrophy amenable to exon 45 skipping. The company plans to start this study in Q3 2025 as part of its broader development strategy, which includes two other exon-skipping programs. Entrada aims to address the urgent needs of patients suffering from progressive diseases through innovative therapeutic approaches.

Feb 27, 2025

TRDAFDA Updates

Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Entrada Therapeutics has reported its financial results for Q4 and the full year 2024, highlighting substantial progress in its Duchenne muscular dystrophy (DMD) programs. The company received FDA and MHRA authorizations to initiate key clinical trials for ENTR-601-44. With a strong cash position of $420 million, Entrada expects its funds to last into mid-2027, facilitating ongoing research and development. Despite increased expenses in R&D, the company remains optimistic about its pipeline and future clinical studies.

Feb 24, 2025

TRDAFDA Updates

Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44

Entrada Therapeutics has announced the FDA's removal of the clinical hold on ENTR-601-44, allowing the initiation of the ELEVATE-44-102 study. This Phase 1b clinical trial aims to evaluate ENTR-601-44 in adults with Duchenne muscular dystrophy, particularly those suitable for exon 44 skipping. The global ELEVATE-44 program will now also include pediatric patients and those in both ambulatory and non-ambulatory stages of the disease. The study seeks to gather crucial data on safety, tolerability, and efficacy as it moves forward towards enrollment in 2026.

Feb 3, 2025

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy

Entrada Therapeutics has received authorization from the UK's Medicines and Healthcare Products Regulatory Agency to initiate ELEVATE-44-201, a Phase 1/2 clinical study of ENTR-601-44 for Duchenne muscular dystrophy. This study aims to evaluate the safety and effectiveness of ENTR-601-44 in patients with specific mutations in the DMD gene. Entrada is on track to begin this study in Q2 2025, which follows the successful Phase 1 trials that demonstrated the investigational therapy was well tolerated. The development represents a significant advancement for patients with limited existing therapeutic options.

Jan 15, 2025

J.P. Morgan Healthcare Conference NASDAQ: TRDA Disclaimer This presentation has been prepared by Entrada Therapeutics, Inc. (the "Company") and shall not constitute an offer to sell o r a solicitation of an offer to buy

Entrada Therapeutics is preparing for significant advancements in 2025, including multiple Phase 1/2 studies for therapies targeting Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). The company has reported a strong cash position of approximately $420 million, enabling further development of its pipeline. Its unique Endosomal Escape Vehicles (EEV) technology is positioned to enhance therapeutic efficacy. Partnerships and milestone payments further support its robust financial outlook.

Dec 18, 2024

▼ -7.3%on this news

Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Entrada Therapeutics, Inc. (Nasdaq: TRDA) will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025. CEO Dipal Doshi will discuss the company's advancements in creating a new class of medicines designed to engage intracellular targets. Entrada's unique Endosomal Escape Vehicle (EEV™) therapeutics aim to improve the delivery of treatment options for various diseases, including neuromuscular and metabolic disorders. Their development portfolio includes promising programs for Duchenne muscular dystrophy and myotonic dystrophy type 1.

Nov 5, 2024

Entrada Therapeutics Reports Third Quarter 2024 Financial Results

Entrada Therapeutics has announced its financial results for Q3 2024, reporting a significant cash position of $449 million and aiming to submit regulatory filings for two clinical trials by the end of the year. The company presented positive data on its drug candidates ENTR-601-44 and ENTR-601-45 at the World Muscle Society Annual Congress, indicating good progress. However, they experienced a considerable drop in collaboration revenue and reported a net loss compared to the previous year. The increase in R&D expenses also indicates growing investments in their drug development pipeline.

Oct 9, 2024

Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society

Entrada Therapeutics has presented new clinical and preclinical data supporting its Duchenne muscular dystrophy (DMD) franchise at the World Muscle Society Congress. The data highlights the safety of ENTR-601-44 from its Phase 1 trial and the promising exon skipping and dystrophin production effects of ENTR-601-45. The company plans to submit regulatory applications for global Phase 2 clinical trials for both candidates in Q4 2024. Additionally, they aim to initiate trials for another candidate, ENTR-601-50, in 2025.

Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development

Entrada Therapeutics has announced the promotion of Dr. Natarajan Sethuraman to President of Research and Development, effective immediately. Dr. Sethuraman has been pivotal to the company since its inception, significantly contributing to the development of its intracellular therapeutics pipeline. His leadership is expected to enhance Entrada's efforts in delivering innovative treatments for patients with serious diseases. The company is focused on making advancements in drug delivery through its proprietary EEV™-therapeutics platform.

Sep 6, 2024

Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program

Entrada Therapeutics has announced the recipients of its second annual DREAMS Grant Program, awarding $25,000 each to three U.S.-based non-profit organizations focused on advancing diversity, equity, inclusion, and accessibility in the Duchenne community. The grant recipients, including CureDuchenne, The Little Hercules Foundation, and Walking Strong, will utilize the funds to improve care and resources for individuals affected by Duchenne muscular dystrophy. This initiative coincides with World Duchenne Awareness Day, emphasizing the importance of amplifying voices within this community.

Entrada Therapeutics Reports Second Quarter 2024 Financial Results

Entrada Therapeutics, Inc. (TRDA) reported its financial results for Q2 2024, highlighting positive outcomes from its Phase 1 trial of ENTR-601-44 for Duchenne muscular dystrophy (DMD). The company plans to initiate global Phase 2 trials for ENTR-601-44 and ENTR-601-45, with regulatory filings expected in Q4 2024. Additionally, Entrada has secured a $100 million financing, ensuring its cash resources will extend into 2027, positioning it to advance its clinical programs.

Jun 24, 2024

Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular Dystrophy - ENTR-601-44 was well-tolerated in healthy volunteers with no serious adver

Entrada Therapeutics announced positive preliminary data from its Phase 1 clinical trial of ENTR-601-44 for Duchenne muscular dystrophy. The trial demonstrated that ENTR-601-44 was well-tolerated with no serious adverse events, and showed significant plasma concentrations, muscle concentrations, and exon skipping. The company is planning to submit regulatory filings for Phase 2 trials in Q4 2024, indicating an advancement towards providing potential treatments for patients. The results support the therapeutic approach of targeting previously inaccessible intracellular elements.

Jun 24, 2024

Entrada Therapeutics Announces $100 Million Registered Direct Offering - The offering was led by a U.S.-based healthcare focused investor, two global mutual funds and Janus Henderson Investors, a global asset management

Entrada Therapeutics announced a registered direct offering of approximately $100 million, led by a healthcare investor and two global mutual funds. The offering includes the sale of 3,367,003 shares of common stock and pre-funded warrants. The proceeds will be used to fund clinical trials for their therapies and for general corporate purposes. The offering is expected to close by June 25, 2024, contingent on customary closing conditions.

Jun 3, 2024

Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference

Entrada Therapeutics, a clinical-stage biopharmaceutical company, announced its CEO Dipal Doshi will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024, in Miami, FL. The event aims to showcase the company's efforts in developing novel therapeutics that target previously inaccessible intracellular targets. A live webcast of the presentation will be available, allowing wider audience engagement and potential investor interest. Entrada's focus includes therapies for various diseases, leveraging their proprietary Endosomal Escape Vehicle technology.

May 16, 2024

Entrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

Entrada Therapeutics, a clinical-stage biopharmaceutical firm, will be presenting at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ. CEO Dipal Doshi will participate in a fireside chat on May 20, 2024. The company's innovative Endosomal Escape Vehicle (EEV™) therapeutics aim to improve intracellular delivery of medicines. Entrada is developing programs for various diseases and has partnerships to enhance treatment options.

May 7, 2024

Entrada Therapeutics Reports First Quarter 2024 Financial Results

Entrada Therapeutics reported its financial results for Q1 2024, highlighting significant clinical advancements. The company initiated dosing for the final cohort of the Phase 1 clinical trial of ENTR-601-44 for Duchenne muscular dystrophy (DMD). It also received a $75 million milestone payment from Vertex Pharmaceuticals. With $327 million in cash and anticipated revenue, Entrada's cash runway is projected to last through mid-2026.

Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

Entrada Therapeutics has reported positive financial results for the fourth quarter and full year 2023, with a cash position of $352 million as of December 31, 2023. The company has completed dosing for the third cohort of its ENTR-601-44 Phase 1 clinical trial aimed at treating Duchenne muscular dystrophy, with data readout expected in the second half of 2024. Regulatory applications for the global Phase 2 development of ENTR-601-44 and ENTR-601-45 are anticipated for submission in the fourth quarter of 2024, indicating a strong clinical pipeline and financial stability going forward.

Entrada Therapeutics Promotes Nathan J. Dowden to President - With a proven track record at Entrada and across his 30-year career in the healthcare sector, Mr. Dowden is well-positioned to help continue driving Entrada's

Entrada Therapeutics has promoted Nathan J. Dowden to President and Chief Operating Officer, effective January 1, 2024. Mr. Dowden, who has been with the company since 2019, is credited with guiding the company's growth and advancing its lead program into clinical development. His extensive experience in the healthcare sector positions him well to drive Entrada's operational strategy and expand its pipeline of intracellular therapeutics. The company aims to deliver innovative medicines that target diseases deemed difficult to treat.

Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy - Company completes dosing of first and second cohorts in Phase 1 clinical trial, ENTR-601-44-101 - - ENTR-601-44 clinical development

Entrada Therapeutics has announced the completion of dosing for the first and second cohorts in its Phase 1 clinical trial of ENTR-601-44 for Duchenne Muscular Dystrophy. The data readout is anticipated in the second half of 2024. However, the company is facing a clinical hold from the U.S. FDA on its Investigational New Drug (IND) application, which has not been lifted despite submissions of additional information. Nonetheless, Entrada has a cash runway projected through 2025, allowing continued operations.

Entrada Therapeutics Reports Third Quarter 2023 Financial Results

Entrada Therapeutics has reported its third quarter 2023 financial results, highlighting the initiation of a Phase 1 clinical trial for ENTR-601-44, aimed at treating Duchenne muscular dystrophy. The company has also expanded its product pipeline with the selection of ENTR-601-50, targeting patients amenable to exon 50 skipping. Furthermore, Entrada's financial health is robust, with $354 million in cash expected to last through 2025. The update includes a pending clinical hold on their IND application with the FDA, which they will address in the upcoming quarter.

Sep 21, 2023

Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy

Entrada Therapeutics has announced the successful dosing of the first participant in its Phase 1 clinical trial of ENTR-601-44, aimed at treating Duchenne muscular dystrophy. This marks a key transition for the company as it shifts towards clinical operations. The trial will evaluate the safety and tolerability of the treatment, with results anticipated in the second half of 2024. ENTR-601-44 is designed to counteract the genetic causes of Duchenne muscular dystrophy by restoring dystrophin protein function.

Entrada Therapeutics Awards Funding to Non-Profit Organizations Advancing Diversity, Equity, Inclusion and Accessibility within the Duchenne Muscular Dystrophy Community

Entrada Therapeutics announced the recipients of its inaugural DREAMS Grant Program, awarding $25,000 each to three non-profit organizations focused on addressing disparities within the Duchenne muscular dystrophy community. The grants are intended to enhance diversity, equity, inclusion, and accessibility for those living with Duchenne. Recipients include The Akari Foundation, Neurology and Neuromuscular Care Center, and Parent Project Muscular Dystrophy, all of which aim to provide resources and support for underrepresented individuals facing challenges related to this condition. The announcement coincided with World Duchenne Awareness Day to highlight the importance of these initiatives.

Aug 10, 2023

Entrada Therapeutics Appoints Gina Chapman to its Board of Directors BOSTON

Entrada Therapeutics has appointed Gina Chapman to its Board of Directors, effective September 1, 2023. Chapman, currently the CEO of CARGO Therapeutics, has over thirty years of experience in the biopharmaceutical sector. Her appointment comes as Entrada prepares to enter a clinical stage with the initiation of its first clinical trial for Duchenne muscular dystrophy. The company aims to leverage its Endosomal Escape Vehicle (EEV) platform to develop therapeutics targeting accessible intracellular disease-causing targets.

Aug 8, 2023

▲ +10.5%on this newsshared move

Entrada Therapeutics Reports Second Quarter 2023 Financial Results

Entrada Therapeutics reported its second quarter 2023 financial results, highlighting the upcoming Phase 1 clinical trial for ENTR-601-44, focusing on Duchenne muscular dystrophy. With a cash position of $377 million, the company is well-funded to pursue its objectives through 2025. The trial, scheduled to start in September, aims to evaluate the safety of ENTR-601-44, while the company is also working to resolve a clinical hold on its IND application with the FDA. Despite an increase in net loss, the company remains optimistic about its prospects and plans for future expansions of its therapeutic portfolio.

Aug 1, 2023

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy - First participant is expected to be dosed i

Entrada Therapeutics has announced the receipt of authorization from the UK Medicines and Healthcare Products Regulatory Agency for a Phase 1 clinical trial of its lead product candidate, ENTR-601-44. This investigational therapy targets potential treatment for individuals with Duchenne muscular dystrophy, specifically those amenable to exon 44 skipping. The first participant is expected to be dosed in September 2023, with data anticipated in the latter half of 2024. Additionally, the company's cash runway has been extended through the end of 2025, which supports their ongoing development efforts.

Jun 6, 2023

▲ +6.5%on this news

Entrada Therapeutics to Present at Goldman Sachs 44th Annual Global Healthcare Conference

Entrada Therapeutics, Inc. announced that CEO Dipal Doshi will participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference on June 14, 2023. The event will focus on the company's innovative Endosomal Escape Vehicle (EEV™)-therapeutics, aimed at transforming the treatment of difficult-to-reach intracellular targets in various diseases. Interested individuals can access a live webcast through the company's Investor Relations page, with a 90-day replay also available.

May 10, 2023

Entrada Therapeutics Reports First Quarter 2023 Financial Results

Entrada Therapeutics has reported its first-quarter financial results for 2023, highlighting a successful collaboration with Vertex for the development of EEV-therapeutics targeting myotonic dystrophy type 1. The company ended the quarter with $412 million in cash, extending its cash runway into the second half of 2025. Despite positive developments, Entrada is still working to resolve a clinical hold on its Investigational New Drug application for ENTR-601-44, while actively pursuing global trials for other therapeutics. The net loss for the quarter decreased compared to the previous year, reflecting strategic growth initiatives.

Entrada Therapeutics Appoints Dr. Bernhardt Zeiher to its Board of Directors

Entrada Therapeutics announced the appointment of Dr. Bernhardt Zeiher to its Board of Directors. Dr. Zeiher, a seasoned life sciences leader and former Chief Medical Officer at Astellas Pharma, brings valuable clinical and regulatory insight. His expertise is expected to support Entrada in advancing its lead programs targeting Duchenne muscular dystrophy and myotonic dystrophy type 1, as well as broadening its therapeutic pipeline. This strategic appointment aligns with Entrada's mission to innovate in intracellular therapeutics.

Mar 29, 2023

Entrada Therapeutics to Participate in Guggenheim Genomic Medicines and Rare Disease Conference

Entrada Therapeutics, a biopharmaceutical firm, announced its participation in the Guggenheim Genomic Medicines and Rare Disease Conference on April 4, 2023. CEO Dipal Doshi will engage in a virtual fireside chat during the event. The company is known for its focus on Endosomal Escape Vehicle (EEV™) therapeutics aimed at targeting previously inaccessible intracellular diseases. This aligns with their goal to improve treatment options for conditions such as muscular and metabolic diseases.

Mar 6, 2023

Entrada Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

Entrada Therapeutics reported its fourth quarter and full year 2022 financial results, highlighting significant progress in its strategic initiatives. The company established a collaboration with Vertex to develop intracellular EEV-therapeutics for myotonic dystrophy and expands its pipeline by selecting ENTR-601-45 for Duchenne therapy. However, the FDA placed a clinical hold on ENTR-601-44, necessitating additional information. Despite a net loss of $94.6 million for 2022, the company has extended its cash runway into the second half of 2025.

Feb 27, 2023

Entrada Therapeutics to Participate in Cowen 43rd Annual Health Care Conference

Entrada Therapeutics, Inc. (Nasdaq: TRDA) will participate in the Cowen 43rd Annual Health Care Conference, presenting insights on its innovative Endosomal Escape Vehicle (EEV™) therapeutics. The panel is scheduled for March 8, 2023, in Boston, MA, and will be led by CEO Dipal Doshi. The company aims to revolutionize intracellular therapies and address previously challenging medical conditions. A live webcast and replay will be available for interested stakeholders.

Feb 9, 2023

Entrada Therapeutics Closes Agreement with Vertex to Discover and Develop Endosomal Escape Vehicle-Therapeutics for Myotonic Dystrophy Type 1 (DM1)

Entrada Therapeutics has closed its strategic collaboration agreement with Vertex, allowing for the development of endosomal escape vehicle therapeutics for myotonic dystrophy type 1. The agreement includes an upfront payment of $224 million and an equity investment of $26 million. Additionally, Entrada may earn up to $485 million based on achieving certain milestones. This collaboration will support Entrada's ongoing research while extending its financial runway into mid-2025.

Entrada Therapeutics Announces Clinical Candidate, ENTR-601-45, for the Potential Treatment of People Living with Duchenne Muscular Dystrophy who are Exon 45 Skipping Amenable

Entrada Therapeutics has announced the selection of ENTR-601-45, a clinical candidate designed for the treatment of individuals with Duchenne muscular dystrophy who are amenable to exon 45 skipping. The decision is supported by preclinical data illustrating high levels of exon skipping and dystrophin restoration in mouse models. The company aims to submit an Investigational New Drug application by the second half of 2024 and plans to present further data at an upcoming conference, indicating ongoing progress in their therapeutic pipeline.

Dec 19, 2022

▼ -6.1%on this news· ran to -27% by day 3

Entrada Therapeutics Announces Clinical Hold on IND Application for ENTR-601-44 in Duchenne Muscular Dystrophy

Entrada Therapeutics Announces Clinical Hold on IND Application for ENTR-601-44 in Duchenne Muscular Dystrophy BOSTON, Monday, December 19, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients

Vertex and Entrada Therapeutics Establish Collaboration to Discover and Develop Endosomal Escape Vehicle (EEV) Therapeutics for Myotonic Dystrophy Type 1 (DM1) - Entrada to receive $224 million upfront payment and $26 mi

Vertex and Entrada Therapeutics Establish Collaboration to Discover and Develop Endosomal Escape Vehicle (EEV) Therapeutics for Myotonic Dystrophy Type 1 (DM1) - Entrada to receive $224 million upfront payment and $26 million equity investment, as well as potential milestone p

Nov 22, 2022

Entrada Therapeutics to Present at Evercore ISI 5th Annual HealthCONx Virtual Conference

BOSTON, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biotechnology company aiming to transform the lives of patients and become the world’s foremost intracellular therapeutics company by establishing Endosomal Escape Vehicle (EEVTM) therapeutics

Document Entrada Therapeutics Reports Third Quarter 2022 Financial Results On track to submit Investigational New Drug application to the U.S. Food and Drug Administration for ENTR-601-44 for the potential treatment of p

Entrada Therapeutics Reports Third Quarter 2022 Financial Results On track to submit Investigational New Drug application to the U.S. Food and Drug Administration for ENTR-601-44 for the potential treatment of patients with Duchenne muscular dystrophy who are exon 44 skipping am

Entrada Therapeutics Reports Third Quarter 2022 Financial Results

On track to submit Investigational New Drug application to the U.S. Food and Drug Administration for ENTR-601-44 for the potential treatment of patients with Duchenne muscular dystrophy who are exon 44 skipping amenable in the fourth quarter of 2022 Cash runway into 2H 2024 with

Aug 30, 2022

Entrada Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference

BOSTON, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today announced that

Aug 11, 2022

Entrada Therapeutics Reports Second Quarter 2022 Financial Results

On track to submit Investigational New Drug application to the U.S. Food and Drug Administration for ENTR-601-44 targeting Duchenne muscular dystrophy in Q4 2022 Cash runway into 2H 2024 with $244 million in cash, cash equivalents and marketable securities as of June 30, 2022 B

Aug 4, 2022

Entrada Therapeutics Announces Collaboration with the Myotonic Dystrophy Clinical Research Network to Study the Natural History of Myotonic Dystrophy Type 1

The natural history study will generate data to further the ongoing efforts of the myotonic dystrophy research community to understand disease progression and identify potential clinical outcome measures and endpoints for clinical trials Entrada recently announced new preclinica

Entrada Therapeutics Appoints Karla MacDonald as Chief Corporate Affairs Officer

BOSTON, July 19, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today announced the a

Jul 6, 2022

Entrada Therapeutics to Present at William Blair Biotech Focus Conference

BOSTON, July 06, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today announced that

Jun 1, 2022

▼ -15.2%on this news

Entrada Therapeutics to Present at Goldman Sachs Global Healthcare Conference

BOSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today announced that

Entrada Therapeutics Reports First Quarter 2022 Financial Results Second clinical candidate, ENTR-701, announced for the potential treatment of myotonic dystrophy type 1 On track to submit Investigational New Drug applic

Entrada Therapeutics Reports First Quarter 2022 Second clinical candidate, ENTR-701, announced for the potential treatment of myotonic dystrophy type 1 On track to submit Investigational New Drug application to the U.S. Food and Drug Administration for ENTR-601-44 targeting D

May 11, 2022

▼ -9.4%on this newsshared move

Entrada Therapeutics Presents New Data Supporting its Growing Pipeline of Endosomal Escape Vehicle (EEV™) Therapeutics at TIDES USA 2022

New non-human primate data demonstrate a durability of response through 12 weeks for lead clinical candidate, ENTR-601-44, for the potential treatment of Duchenne muscular dystrophy Second clinical candidate, ENTR-701, announced for the potential treatment of myotonic dystrophy

May 10, 2022

▲ +13.8%on this newsshared move

Entrada Therapeutics to Present at H.C. Wainwright Global Investment Conference

BOSTON, May 10, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today announced that D

Mar 15, 2022

▲ +9.8%on this news· ran to +20% by day 3

Entrada Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results On track to submit IND application for ENTR-601-44 targeting Duchenne muscular dystrophy in 2H 2022 $291.1 million in cash and cash equival

Entrada Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results On track to submit IND application for ENTR-601-44 targeting Duchenne muscular dystrophy in 2H 2022 $291.1 million in cash and cash equivalents as of December 31, 2021 to advance pipeline of EEV

Feb 23, 2022

▼ -17.2%on this news

Entrada Therapeutics to Participate in Cowen 42nd Annual Health Care Conference

BOSTON, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today announced that

Jan 5, 2022

▼ -15.4%on this news· ran to -30% by day 3

Entrada Therapeutics Announces the Appointment of Jared Cohen, PhD, JD to General Counsel

BOSTON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today announced that

Dec 17, 2021

Entrada Therapeutics to be Added to Russell 2000 and Russell 3000 Indexes

BOSTON, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today announced that

Dec 9, 2021

Entrada Therapeutics Reports Third Quarter 2021 Financial Results Successful completion of upsized $208.7 million Initial Public Offering

Entrada Therapeutics Reports Third Quarter 2021 Successful completion of upsized $208.7 million Initial Public Offering BOSTON, Mass., December 9, 2021 - Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establ

Nov 18, 2021

Entrada Therapeutics to Present at Evercore ISI 4th Annual HealthCONx Virtual Conference

BOSTON, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biotechnology company aiming to transform the lives of patients and become the world’s foremost intracellular therapeutics company by establishing Endosomal Escape Vehicle (EEV™) therapeutics a

Entrada Therapeutics Announces Closing of Initial Public Offering

BOSTON, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biotechnology company aiming to transform the lives of patients by establishing Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines and aiming to become the world’s foremos

Oct 29, 2021